IN THE CLAIMS:

Please cancel claims 2-6, 8, 9, 11, 20, 24-29, 35 and 36, amend claims 1 and 16, and add new claims 55-76 as follows.

This listing of claims will replace all prior versions, and listings of the claims in the application.

Listing of the claims

1. (currently amended). An isolated nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of:

a nucleic acid sequence that encodes a non-immunogenic fusion protein that comprises a non-IL-15 signal peptide linked to IL-15 protein or a functional fragment thereof, a nucleic acid sequence that encodes a fusion protein that comprises IL-15 protein or a functional fragment thereof, linked to a non-IL-15 signal peptide that is from a gene that is from the same species as the IL-15;

a nucleic acid sequence that encodes IL-15 protein or a functional fragment thereof and a nucleotide sequence that encodes CD40L or a functional fragment thereof;

a nucleic acid sequence that encodes a fusion protein that consists of a non-IgE protein sequences linked to a IgE signal peptide that is from the same species as the non-IgE protein; and

a nucleic acid sequence that encodes a fusion protein that consists of a non-IgE protein sequences linked to a IgE signal peptide wherein the non-IgE protein is an immunomodulating protein.

2-13 (canceled).

- **SERIAL NO.** 10/560,650 **FILED:** May 9, 2006
- 14. (previously presented). The isolated nucleic acid molecule of claim 1 wherein said isolated nucleic acid molecule is a plasmid.
- 15. (previously presented). The nucleic acid molecule of claim 1 incorporated into a viral vector.
- 16. (currently amended). A composition selected from the group consisting of:

 a composition comprising a nucleic acid molecule of claim 1 and a nucleic acid molecule that comprises a nucleic acid sequence that encodes an immunogen.; and
 a composition that comprises a nucleic acid molecule that comprises a nucleic acid sequence that encodes IL-15 protein and a nucleic acid molecule that comprises a nucleotide sequence that encodes CD4QL protein.
- 17. (previously presented). The composition of claim 16 wherein said composition comprises a nucleic acid molecule that encodes an immunogen, wherein said immunogen is a pathogen antigen, a cancer-associated antigen or an antigen linked to cells associated with autoimmune diseases.
- 18. (canceled).
- 19. (previously presented). The composition of claim 17 wherein said immunogen is a pathogen antigen is from a pathogen selected from the group consisting of HIV, HSV, HCV, and WNV.
- 20. (canceled).
- 21. (previously presented). An injectable pharmaceutical composition comprising the nucleic acid molecules of claim 1.

DOCKET NO. UPAP0020-100 PATENT

- 22. (previously presented). An recombinant vaccine comprising the nucleic acid molecules of claim 1.
- 23. (previously presented). The recombinant vaccine of claims 22 wherein said recombinant vaccine is a recombinant vaccine.

SERIAL NO. 10/560,650

FILED: May 9, 2006

- 24-37 (canceled).
- 38. (previously presented). The isolated nucleic acid molecule of claim 1 wherein said isolated nucleic acid molecule comprises a nucleic acid sequence that encodes a fusion protein that consists of an IgE signal peptide linked to non-IgE protein sequences wherein the non-IgE protein is an enzyme or functional fragment thereof.
- 39-53. (canceled).
- 54. (previously presented). An injectable pharmaceutical composition comprising the composition of claim 16.
- 55. (new). The isolated nucleic acid molecule of claim 1 comprising a nucleic acid sequence that encodes a fusion protein that consists of a non-IgE protein sequences linked to a IgE signal peptide that is from the same species as the non-IgE protein.
- 56. (new). The isolated nucleic acid molecule of claim 55 wherein said isolated nucleic acid molecule is a plasmid.
- 57. (new). The nucleic acid molecule of claim 55 incorporated into a viral vector.

- **SERIAL NO.** 10/560,650 **FILED:** May 9, 2006
- 58. (new). A composition comprising a nucleic acid molecule of claim 55 and a nucleic acid molecule that comprises a nucleic acid sequence that encodes an immunogen.
- 59. (new). The composition of claim 58 wherein said composition comprises a nucleic acid molecule that encodes an immunogen, wherein said immunogen is a pathogen antigen, a cancer-associated antigen or an antigen linked to cells associated with autoimmune diseases.
- 60. (new). The composition of claim 59 wherein said immunogen is a_pathogen antigen is from a pathogen selected from the group consisting of HIV, HSV, HCV, and WNV.
- 61. (new). An injectable pharmaceutical composition comprising the nucleic acid molecules of claim 55.
- 62. (new). An recombinant vaccine comprising the nucleic acid molecules of claim 55.
- 63. (new). The recombinant vaccine of claims 62 wherein said recombinant vaccine is a recombinant vaccinia vaccine.
- 64. (new). The isolated nucleic acid molecule of claim 55 wherein said isolated nucleic acid molecule comprises a nucleic acid sequence that encodes a fusion protein that consists of an IgE signal peptide linked to non-IgE protein sequences wherein the non-IgE protein is an enzyme or functional fragment thereof.

- 65. (new). An injectable pharmaceutical composition comprising the composition of claim 58.
- 66. (new). The isolated nucleic acid molecule of claim 1 comprising a nucleic acid sequence that encodes a fusion protein that consists of a non-IgE protein sequences linked to a IgE signal peptide wherein the non-IgE protein is an immunomodulating protein.
- 67. (new). The isolated nucleic acid molecule of claim 66 wherein said isolated nucleic acid molecule is a plasmid.
- 68. (new). The nucleic acid molecule of claim 66 incorporated into a viral vector.
- 69. (new). A composition comprising a nucleic acid molecule of claim 66 and a nucleic acid molecule that comprises a nucleic acid sequence that encodes an immunogen.
- 70. (new). The composition of claim 69 wherein said composition comprises a nucleic acid molecule that encodes an immunogen, wherein said immunogen is a pathogen antigen, a cancer-associated antigen or an antigen linked to cells associated with autoimmune diseases.
- 71. (new). The composition of claim 70 wherein said immunogen is a pathogen antigen is from a pathogen selected from the group consisting of HIV, HSV, HCV, and WNV.
- 72. (new). An injectable pharmaceutical composition comprising the nucleic acid molecules of claim 66.

DOCKET NO. UPAP0020-100 PATENT

- **SERIAL NO.** 10/560,650 **FILED:** May 9, 2006
- 73. (new). An recombinant vaccine comprising the nucleic acid molecules of claim 66.
- 74. (new). The recombinant vaccine of claims 73 wherein said recombinant vaccine is a recombinant vaccinia vaccine.
- 75. (new). The isolated nucleic acid molecule of claim 66 wherein said isolated nucleic acid molecule comprises a nucleic acid sequence that encodes a fusion protein that consists of an IgE signal peptide linked to non-IgE protein sequences wherein the non-IgE protein is an enzyme or functional fragment thereof.
- 76. (new). An injectable pharmaceutical composition comprising the composition of claim 69.